It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19).

Timothée, Klopfenstein; Gerazime, Aurélie; Puyraveau, Marc; Kadiane-Oussou, N'dri Juliette; Gendrin, Vincent; Zayet, Souheil

Timothée, Klopfenstein; Gerazime, Aurélie; Puyraveau, Marc; Kadiane-Oussou, N'dri Juliette; Gendrin, Vincent; Zayet, Souheil.

Afiliação

Timothée K; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
Gerazime A; Methodology Unit, Clinical Investigation Center, INSERM 1431, Jean-Minjoz University Hospital, Besançon, France.
Puyraveau M; Methodology Unit, Clinical Investigation Center, INSERM 1431, Jean-Minjoz University Hospital, Besançon, France.
Kadiane-Oussou NJ; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
Gendrin V; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.
Zayet S; Infectious Disease Department, Nord Franche-Comté Hospital, Trevenans, France.

Clin Infect Dis ; 74(3): 560-562, 2022 02 11.

Article em En | MEDLINE | ID: mdl-34036334

Assuntos

Tratamento Farmacológico da COVID-19; Anticorpos Monoclonais Humanizados; Humanos; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google